Prescriber Criteria Form

Augtyro 2025 PA Fax 6262-A v2 010125.docx Augtyro (repotrectinib) Coverage Determination

This fax machine is located in a secure location as required by HIPAA regulations.

Drug Name:

Complete/review information, sign and date. Fax signed forms to CVS Caremark at **1-855-633-7673.** Please contact CVS Caremark at **1-866-785-5714** with questions regarding the prior authorization process. When conditions are met, we will authorize the coverage of Augtyro (repotrectinib).

Augtyro (repotrectinib)				
Patient Name:				
Patient ID:				
Patient DOB:	Patient Phone:	Patient Phone:		
Prescriber Name:	·			
Prescriber Address:				
City:	State:	Zip:		
Prescriber Phone:	Prescriber Fax:			
Diagnosis:	ICD Code(s):			

Does the patient have a diagnosis of non-small cell lung cancer (NSCLC)?	Yes	No
[If no, then skip to question 4.]		
Is the tumor positive for proto-oncogene tyrosine-protein kinase ROS1 (ROS1)?	Yes	No
[If no, then no further questions.]		
Is the disease locally advanced or metastatic?	Yes	No
[No further questions.]		
Does the patient have a diagnosis of solid tumor?	Yes	No
[If no, then no further questions.]		
Does the patient have a tumor with neurotrophic tyrosine receptor kinase (NTRK) gene	Yes	No
fusion?		
[If no, then no further questions.]		
Is the disease locally advanced or metastatic?	Yes	No
[If yes, then skip to question 8.]		
Will surgical resection likely result in severe morbidity?	Yes	No
[If no, then no further questions.]		
	[If no, then no further questions.] Is the disease locally advanced or metastatic? [No further questions.] Does the patient have a diagnosis of solid tumor? [If no, then no further questions.] Does the patient have a tumor with neurotrophic tyrosine receptor kinase (NTRK) gene fusion? [If no, then no further questions.] Is the disease locally advanced or metastatic? [If yes, then skip to question 8.] Will surgical resection likely result in severe morbidity?	Is the tumor positive for proto-oncogene tyrosine-protein kinase ROS1 (ROS1)? [If no, then no further questions.] Is the disease locally advanced or metastatic? [No further questions.] Does the patient have a diagnosis of solid tumor? [If no, then no further questions.] Does the patient have a tumor with neurotrophic tyrosine receptor kinase (NTRK) gene fusion? [If no, then no further questions.] Is the disease locally advanced or metastatic? [If yes, then skip to question 8.] Will surgical resection likely result in severe morbidity? Yes

Presci	iber (or Authorized) Signature: Date:		
docum	entation supporting this information is available for review if requested by the health plan	1.	
By sigr	ning this form, I attest that the information provided is accurate and true as of this date ar	nd that the	
Comm	ents:		
		L	
9	Are any satisfactory alternative therapies available for the disease?		No
9	And any posting stomy altermative the arguing available for the discuss 2	Yes	Nia
	[If yes, then no further questions.]		
8	Has the disease progressed following treatment?	Yes	No